Risk Assessment Model of Trastuzumab-related Cardiotoxicity in Breast Cancer Patients
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Locations
-
-
Beijing
-
Peking, Beijing, China, 100191
- Recruiting
- Peking University Third Hospital
-
Contact:
- Xin Liu
- Phone Number: 18801362704
- Email: liuxinlucile2019@163.com
-
Contact:
- Weixian Xu
- Phone Number: 13810695447
- Email: xwxbird05@163.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Female patients diagnosed with HER2-positive breast cancer treated in our hospital.
- Surgical treatment combined with chemotherapy or radiotherapy was completed according to NCCN guidelines, and trastuzumab standard treatment was received for at least half a year.
(3) Cardiac function (including echocardiography or biomarkers) was assessed at least once within 3 months before trastuzumab treatment, and at least once during or after treatment was performed for heart-related tests.
(4) Complete case data.
Exclusion Criteria:
- Patients who have not been properly treated with trastuzumab or have been treated for less than half a year;
- Patients who did not receive cardiac function assessment before trastuzumab treatment, during or after treatment;
- Patients whose case data were missing or lost to follow-up.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
The case group
Trastuzumab for the treatment of breast cancer patients with cardiotoxicity.
|
Trastuzumab [Herceptin] is a recombinant DNA-humanized monoclonal antibody that selectively targets the HER-2 receptor on the surface of tumor cells.
|
|
The control group
Trastuzumab is used to treat patients with breast cancer who do not present with cardiotoxicity
|
Trastuzumab [Herceptin] is a recombinant DNA-humanized monoclonal antibody that selectively targets the HER-2 receptor on the surface of tumor cells.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Cardiac toxicity
Time Frame: 12 months
|
The asymptomatic LVEF decreases ≥ 10% of the baseline value or to an absolute value < 50%
|
12 months
|
|
Cardiac toxicity
Time Frame: 12 months
|
acute or chronic heart failure
|
12 months
|
|
Cardiac toxicity
Time Frame: 12 months
|
New or aggravated arrhythmias or coronary heart disease
|
12 months
|
|
Cardiac toxicity
Time Frame: 12 months
|
Myocardial infarction or other cardiac death
|
12 months
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Chemically-Induced Disorders
- Pathologic Processes
- Heart Diseases
- Cardiovascular Diseases
- Skin Diseases
- Neoplasms
- Neoplasms by Site
- Wounds and Injuries
- Breast Diseases
- Drug-Related Side Effects and Adverse Reactions
- Radiation Injuries
- Breast Neoplasms
- Cardiotoxicity
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Trastuzumab
Other Study ID Numbers
Other Study ID Numbers
- Cardiotoxicity study
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.